Fashion

Puig Sets an €8 Billion Sales Target for 2032, but Its Shares Slip on the Day

At its first Capital Markets Day as a listed company, the Spanish beauty group promised more than €8 billion in sales and a higher margin by 2032. Investors reacted coolly.

Puig Sets an €8 Billion Sales Target for 2032, but Its Shares Slip on the Day
The Madrid Stock Exchange, where Puig shares are listed. Photo: Fernando / Wikimedia Commons (CC BY-SA 4.0)

Key takeaways

  • Puig aims to pass €8 billion in annual net sales by 2032, up from €5,042 million in 2025, with an adjusted EBITDA margin above 22.5%.
  • The plan rests on prestige and niche fragrance, Charlotte Tilbury and a larger dermocosmetics business built around Isdin, Uriage and Apivita.
  • The shares closed down 2.66% on the day, as reports named Puig among the possible buyers of the perfume house Parfums de Marly.

Puig, the Spanish group behind Rabanne, Jean Paul Gaultier, Carolina Herrera, Byredo and Charlotte Tilbury, set out a long-range plan on Wednesday 28 October. Named Vision 2032, it targets net sales above €8 billion by 2032, compared with €5,042 million reported for 2025, roughly 60% higher, according to Next In Beauty. The group also wants to lift its adjusted EBITDA margin from 20.7% to more than 22.5%.

The presentation in Madrid was Puig’s first Capital Markets Day since it listed, and, according to Merca2, its first public guidance since then. The market’s first verdict was lukewarm: the shares closed 2.66% lower, on a day when reports also linked the company to a possible bid for another perfume house.

The Targets in Detail

Beyond the sales goal, Puig set several financial markers for 2032. Adjusted EBITDA, a measure of operating earnings, is to exceed €1.8 billion. Free cash flow conversion is to stay above 50% of EBITDA, which the company equates with more than €900 million of cash in 2032, and the dividend payout is to remain at 40% of net profit. Puig also states its ambition to rank among the four largest premium beauty companies and among the top two global fragrance players.

Reaching €8 billion from €5,042 million implies average growth of roughly 7% a year over seven years. Puig estimates that the premium beauty market itself will grow 4% to 5% a year, so the plan assumes the group keeps outpacing its sector. Chief executive José Manuel Albesa said the group expects to deliver the ambition "primarily through organic growth", according to Cosmetics Business. Puig describes the plan as a way to "scale what works".

Puig also gave a sense of how far it has come. Net revenues exceeded €5 billion in 2025, which the group says more than tripled its sales over the last five years.

Puig Vision 2032 Targets

Net sales above €8 billion by 2032, against €5,042 million in 2025. Adjusted EBITDA margin above 22.5% (20.7% in 2025) and EBITDA above €1.8 billion. Cash conversion above 50% of EBITDA and a 40% dividend payout. Puig shares closed at €18.67 on 28 October, down 2.66%.

Four Areas Carry the Growth

Prestige fragrance is the first. Puig says women’s perfumes account for about 65% of the global prestige fragrance market but only about 45% of its own prestige fragrance business, so it sees room to grow there. Carolina Herrera is to become a brand that spans both perfume and make-up, while Rabanne and Jean Paul Gaultier keep building their fragrance lines, including Gaultier’s La Favorite, due in 2026.

Niche fragrance, meaning smaller and more exclusive perfume houses, is the second. Byredo and Penhaligon’s are to scale through productivity gains and selective expansion, particularly in the United States, which accounts for 25% of the niche fragrance market. Puig calls niche its fastest-growing division, and estimates that niche will reach about a fifth of the global selective fragrance market by 2032.

Charlotte Tilbury is the third. Puig wants to multiply the brand’s business by 1.5 times by 2032 through make-up growth, a greater focus on skincare, selective distribution gains and a move into fragrance from 2028. The brand has more than tripled in size since Puig bought it in 2020.

The fourth is dermocosmetics, or medically inspired skincare. Puig is taking full ownership of Isdin, which generated about €650 million in 2025, with completion expected in the first quarter of 2027, subject to regulatory approvals. It plans to double the size of Uriage by 2032, and together with Apivita it would build a platform with more than €1 billion in pro forma net revenue. Next In Beauty adds that Dr. Barbara Sturm, acquired in 2024, has not delivered the results expected.

Where the Growth Is Expected to Come From

Puig says it will strengthen its core positions in Europe, the Middle East and Africa, Latin America and travel retail, and accelerate in North America and Asia-Pacific. In travel retail, it rose from sixth to third-largest fragrance player since 2021, and its market share climbed from 9.6% to 13.0%. Asia-Pacific is growing by more than 15% this year, according to Next In Beauty.

Digital is another priority. The group plans to expand through omnichannel and pure-play partners, marketplaces, social commerce and its own e-commerce platforms. FashionUnited notes that the plan includes no initiatives for the fashion side of the business: fashion houses feature as vehicles for perfumes and cosmetics.

Reaching €8 billion from €5,042 million implies average growth of roughly 7% a year over seven years.

A Cool Reception From Investors

Puig shares opened at €19.16, a touch below the previous close of €19.18, and finished the day at €18.67. That was the first close under €19 since 13 October, and it leaves the stock 23.80% below the €24.50 initial public offering price of 3 May 2024. FashionUnited said the close sat about 8.61% below the consensus target price of €20.43, with analyst estimates ranging from €16 to €24.40.

Before the event, analysts had been broadly constructive. Renta 4 Banco raised its price target to €22.60. Several firms expected make-up and skincare to drive medium-term growth while fragrances and fashion lagged the group average, and the main risk they flagged was sales concentrated in a small number of brands, according to Merca2. The Isdin stake, which Puig is buying from Esteve for €1.2 billion, is expected to dilute margins at first.

The plan also follows a failed merger approach. In May, Puig broke off talks on a business combination with the US group Estée Lauder. Executive chairman Marc Puig told shareholders at the time that the majority shareholders intend to stay for the long term, saying "No estamos en venta" ("We are not for sale"), as reported by the Catalan outlet Ara.

The Parfums de Marly Question

Reports on 28 October named Puig among suitors for Parfums de Marly, the French niche perfume house founded in 2009 by Julien Sprecher. The US private equity firm Advent International bought it in 2023 and is reportedly looking to sell. Its fragrances retail for between €175 and €300.

FashionUnited, citing Reuters sources, said the talks are based on a valuation close to €2 billion and that the private equity groups CVC Capital Partners and Cinven are also reported to be contenders. Puig appears to be the least advanced of the three in its discussions with Advent. Puig declined to comment.

Puig has said it expects to grow mainly organically, with selective acquisitions as a complement. Its stated criteria for such deals are "differential brands, new capabilities or presence in attractive categories and markets", according to Next In Beauty. Puig calls niche fragrance its fastest-growing division, according to Cosmetics Business.

Sources